Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 TCR-engineered T-cell therapy
- Development stage
- Unknown
- Lead developer
- UCLA Jonsson Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intradermal, Subcutaneous
01
Overview
NY-ESO-1 TCR-engineered T-cell therapy is an investigational adoptive cell therapy developed by the Jonsson Comprehensive Cancer Center (UCLA) for the treatment of advanced malignancies expressing the NY-ESO-1 antigen. The therapy utilizes autologous peripheral blood lymphocytes (PBL) that are genetically modified via a retroviral vector to express a T-cell receptor (TCR) specific for the NY-ESO-1:157-165 peptide presented by HLA-A*0201. In clinical protocols (such as NCT00924326), this cell therapy is administered following a lymphodepleting conditioning regimen of cyclophosphamide and fludarabine. The treatment is further augmented by the administration of a dendritic cell vaccine pulsed with the NY-ESO-1 peptide and systemic aldesleukin (IL-2) to promote the expansion and persistence of the engineered T cells in vivo.
- Other names
- 1-Jonsson Comprehensive Cancer Center-malignant neoplasm
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)L antigen family member 1-derived peptide/human leukocyte antigen class I complex
Beyond the preview
Go deeper on NY-ESO-1 TCR-engineered T-cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-ESO-1 TCR-engineered T-cell therapy.